Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) Valuation According To Analysts

Share

(NASDAQ:MDRX)'s stock to Buy with no specific Price Target. Leerink Swann reaffirmed an outperform rating and issued a $17.00 price objective on shares of Allscripts Healthcare Solutions in a research note on Friday, September 23rd.

The Stock fell -0.16% and closed its last trading session at $12.43.

Several company insiders have filed Insider transactions, on Sep 16, 2016, Paul Black (CEO) sold 15,000 shares at $13.00 per share price. Both the RSI indicator and target price of and $13.83 respectively, lead us to believe that it could rise over the coming weeks. Before Earnings Announcement on 08/04/2016, the firm had its stock price of $14.27.

Allscripts Healthcare Solutions, Inc. will next provide financial results for the March 2017 quarter. Post-earnings, MDRX stock ranged between $10.11 and $11.3 after opening the day (11/04/2016) at $10.75.

Five judges appointed to the Supreme Court after a long wait
The fresh appointments will take the number of Supreme Court judges to 28, still three short of the court's full strength. In April past year , the collegium had transferred Justice Joseph to the Andhra Pradesh High Court on medical grounds.

12/13/2016 - Allscripts Healthcare Solutions, Inc. was downgraded to "underweight" by analysts at Morgan Stanley. They now have a United States dollars 15 price target on the stock.

Nonetheless, and in the immediate aftermath of reporting, investor reaction in Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) now has a consensus Price Target of $13.89. The stock is going forward its fifty-two week low with 27.04% and lagging behind from its 52-week high price with -17.93%. Canaccord Genuity set a $19.00 price objective on Allscripts Healthcare Solutions and gave the company a "buy" rating in a research report on Thursday, October 27th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company.

Allscripts Healthcare Solutions, Inc.is expected* to report earnings on 02/16/2017 after market close. ( MDRX ) reported earnings for its fourth quarter that rose from previous year. The average revenue estimate for the year ending December 2016 is $776.62M by 15 analysts. The difference between the actual and expected EPS is $0.12 a share with a surprise factor of 15.2%. (MDRX) reported Q2 earnings of $0.14, matching consensus estimates of $0.14. Thus Surprise Factor was there with 0 percent.

Excluding items, adjusted earnings for the quarter were $0.14 per share, up from $0.13 per share a year ago. The firm touched its 52-Week high on Aug 5, 2016 and 52-Week low on Nov 9, 2016. The company has a 1 Year high price target of $13.89.

Trump to launch major review of spy agencies amid 'illegal' leaks
The Wall Street Journal reported that some intelligence officials did not have confidence in Trump. The president has railed against government leaks in the past few days.

The firm is trading with SMA20 of 6.18 Percent, SMA50 of 6.88 Percent and SMA200 of 32.52 percent. (NASDAQ:MDRX) is now showing its ROA (Return on Assets) of -0.1%.

The Company now has ROA (Return on Assets) of -0.1 percent, Return on Equity (ROE) of -0.1 Percent and Return on Investment (ROI) of 1.4% with Gross margin of 43.4 percent and Operating & Profit margin of 4.8% and -0.1% respectively. Similar, the positive performance for the quarter recorded as 29.71% and for the year was 148.17%, while the YTD performance remained at 21.45%. The shares, which traded within a range of $20.7 to $21.25 during the day, are up by 6.68% in the past three months and up by 16.44% over the past six months.

Allscripts Healthcare Solutions, Inc. offers clinical software, services, information and connectivity solutions that enable physicians and healthcare providers to deliver patients safety and clinical outcomes in the US. In the final minutes of trading on Thursday, shares hit $12.42, a drop of slightly more than 2 percent in the last 12 months.

Here's the 'Love Actually' Reunion You've All Been Waiting For
It has been written by Love Actually's director Richard Curtis , who was on set on Thursday when filming kicked off. The last time we saw Sam, he was an adorable young blondie who had just gotten the ideal first kiss in an airport.

Share